Title : Improvement in in vitro fertilization outcome following in vivo synchronization of oocyte maturation in mice.

Pub. Date : 2015 Apr

PMID : 25245076






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Cilostazol phosphodiesterase 3A, cGMP inhibited Mus musculus
2 Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Cilostazol phosphodiesterase 3A, cGMP inhibited Mus musculus
3 Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Cilostazol phosphodiesterase 3A, cGMP inhibited Mus musculus
4 The capability of a clinically approved PDE3A inhibitor to improve oocyte fertilization rates in mice at doses extrapolated from human therapeutic doses suggests the potential scenario of the inclusion of CLZ in superovulation programs. Cilostazol phosphodiesterase 3A, cGMP inhibited Mus musculus